• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response to: Correspondence on 'Current myositis clinical trials and tribulations' by Saygin .

作者信息

Saygin Didem, Werth Victoria, Paik Julie J, Park Jin Kyun, Needham Merrilee, Lundberg Ingrid E, Christopher-Stine Lisa

机构信息

Department of Medicine, Division of Rheumatology, University of Pittsburgh Medical Center, Pittburgh, Pennsylvania, USA

Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

出版信息

Ann Rheum Dis. 2024 Oct 21;83(11):e23. doi: 10.1136/ard-2024-225762.

DOI:10.1136/ard-2024-225762
PMID:38548313
Abstract
摘要

相似文献

1
Response to: Correspondence on 'Current myositis clinical trials and tribulations' by Saygin .对Saygin所著《关于“当前肌炎临床试验与磨难”的通信》的回复。
Ann Rheum Dis. 2024 Oct 21;83(11):e23. doi: 10.1136/ard-2024-225762.
2
Correspondence on 'Current myositis clinical trials and tribulations' by Saygin .关于Saygin的《当前肌炎临床试验与困境》的通信
Ann Rheum Dis. 2024 Oct 21;83(11):e22. doi: 10.1136/ard-2024-225751.
3
Current myositis clinical trials and tribulations.当前肌炎临床试验的困境
Ann Rheum Dis. 2024 Jun 12;83(7):826-829. doi: 10.1136/ard-2023-224652.
4
Inflammatory myopathies.炎性肌病
Continuum (Minneap Minn). 2013 Dec;19(6 Muscle Disease):1615-33. doi: 10.1212/01.CON.0000440662.26427.bd.
5
Response to: 'Comment on: 'Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis' by Sabbagh S by Yang .对Yang的回复：“对Sabbagh S的‘评论：抗Ro52自身抗体与青少年皮肌炎患者的间质性肺疾病及更严重疾病相关’的评论” 。
Ann Rheum Dis. 2020 Aug;79(8):e97. doi: 10.1136/annrheumdis-2019-215693. Epub 2019 Jun 17.
6
Response to: 'Comment on: standardisation of myositis-specific antibodies: where are we today?' by Infantino .
Ann Rheum Dis. 2021 Jul;80(7):e116. doi: 10.1136/annrheumdis-2019-216248. Epub 2019 Oct 15.
7
Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis.在一组大型多发性肌炎和皮肌炎患者中，肌炎特异性和肌炎相关性自身抗体谱及其与临床的相关性。
Clinics (Sao Paulo). 2013 Jul;68(7):909-14. doi: 10.6061/clinics/2013(07)04.
8
Performance of the 2016 ACR-EULAR Myositis Response Criteria in adult dermatomyositis/polymyositis therapeutic trials and consensus profiles.2016ACR-EULAR 肌炎反应标准在成人皮肌炎/多发性肌炎治疗试验和共识标准中的表现。
Rheumatology (Oxford). 2023 Nov 2;62(11):3672-3679. doi: 10.1093/rheumatology/kead110.
9
Comments: Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis.评论：一大系列多发性肌炎和皮肌炎患者的肌炎特异性和肌炎相关性自身抗体谱及其临床关联
Clinics (Sao Paulo). 2022 Jul 23;77:100077. doi: 10.1016/j.clinsp.2022.100077. eCollection 2022.
10
Dr. Noda, reply.
J Rheumatol. 2018 Mar;45(3):441. doi: 10.3899/jrheum.171244.

引用本文的文献

1
Reply to: Current classification criteria underestimate the incidence of idiopathic inflammatory myopathies by ignoring subgroups.回复：当前的分类标准因忽略亚组而低估了特发性炎性肌病的发病率。
Nat Rev Rheumatol. 2024 May;20(5):313-314. doi: 10.1038/s41584-024-01106-8.